Investors / Japan / AN Venture Partners
AN Venture Partners
Venture capital · Tokyo, Japan · Asia Pacific
AN Venture Partners is a Tokyo and San Francisco-based biotech venture capital firm that bridges science from Japan with the US startup ecosystem. It builds and finances companies in the US originating from Japanese science and syndicates with global venture investors.
Invests inHealthcare & Biotech
In its own wordsbiotechlife sciencestherapeuticsjapanus
Your fit with AN Venture Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAN Venture Partners lists 7 checked portfolio companies on its own site and is named in 5 funding rounds, 2 of them as lead. Its most frequent entry is Series A, 75% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside RA Capital, ARCH Venture Partners and Altitude Life Science Ventures.
Counts come from funding rounds that name AN Venture Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundAN Venture Partners does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 75% |
| Series B | 25% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 4 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 12th | 7 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 100th | 57% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 3 |
| ARCH Venture Partners | 1 |
| Altitude Life Science Ventures | 1 |
| Casdin Capital | 1 |
| Catalio Capital Management | 1 |
| Catalys Pacific | 1 |
| Cure Ventures | 1 |
| Cyan Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers7100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare AN Venture Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with AN Venture Partners| Date | Company | Stage |
|---|---|---|
| 2 Sept 2026 | Series A Led | |
| 22 Jul 2026 | Series B | |
| 8 Jun 2026 | Series B | |
| 21 Apr 2026 | Series A Led | |
| 30 Sept 2025 | Series A |
Round details for AN Venture Partners
Amounts, full round histories and every co-investor in AN Venture Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
7 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Capacity Bio develops small molecules, peptides, and nanoparticles to enhance identification of dysfunctional mitochondria and promote clearance by autophagosomes and lysosomes | Healthcare & Biotech | Portfolio page | ||
| City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNAi therapeutics designed to silence the expression of disease-relevant proteins | Healthcare & Biotech | Jun 2026Series B | Page + round | |
| Crystalys Therapeutics develops new therapeutics to address unmet medical needs, specifically for people living with gout. | Healthcare & Biotech | Sept 2025Series A · 2 rounds | Page + round | |
| Imbria develops novel treatments for cardiovascular diseases by enhancing or restoring the cell's ability to produce and use energy | Healthcare & Biotech | Portfolio page | ||
| PAhR Therapeutics is a clinical-stage company focused on developing novel mechanisms for the treatment of pulmonary arterial hypertension (PAH) | Healthcare & Biotech | Portfolio page | ||
| Tortugas Neuroscience develops drugs for neurology and neuropsychiatry | Healthcare & Biotech | Apr 2026Series A | Page + round | |
| Typewriter Therapeutics is building genetic medicines with the potential for durable, curative impact on patients with cancer, autoimmune and severe genetic diseases | Healthcare & Biotech | Sept 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- an.vc
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 30 Sept 2025
- Companies checked
- 7
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get AN Venture Partners' profile as data
Pull AN Venture Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/an.vc
# also
GET /v1/firms/an.vc/portfolio
GET /v1/firms/an.vc/coinvestors
GET /v1/firms/an.vc/news